Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Wallace

Clinical Cardiac Electrophysiology Little Rock, AR Medical Doctor

NPI 1295807733 CMS profile 797644

10100 Kanis Rd, Little Rock, AR 72205

Open in the dashboard

General payments

$13,777

218 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$101,633 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Thomas Wallace of Little Rock, AR is reported in the CMS Open Payments database as having received $13,777 across 218 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $101,633 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 41st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $642 24
2024 General $1,064 26
2023 General $1,739 47
2022 General $1,371 23
2021 General $2,362 21
2020 General $4,321 19
2019 General $2,278 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Wallace
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Thomas Wallace were reported at $642. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Thomas Wallace Clinical Cardiac Electrophysiology median Middle half National median
2019 $2,278 $2,361 $585–$8,260 $163
2020 $4,321 $993 $247–$4,351 $114
2021 $2,362 $1,185 $326–$4,739 $132
2022 $1,371 $2,073 $554–$6,789 $149
2023 $1,739 $2,568 $759–$8,159 $160
2024 $1,064 $2,557 $703–$7,403 $164
2025 $642 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biosense Webster, Inc. $7,204 32 payments
  2. Medtronic, Inc. $1,604 21 payments
  3. Abbott Laboratories $973 15 payments
  4. Medical Device Business Services, Inc. $923 3 payments
  5. Novartis Pharmaceuticals Corporation $675 53 payments
  6. Medtronic Vascular, Inc. $617 11 payments
  7. Boston Scientific Corporation $291 12 payments
  8. Atricure, Inc. $281 3 payments
  9. E.R. Squibb & Sons, L.L.C. $188 12 payments
  10. AltaThera Pharmaceuticals LLC $145 1 payment
  11. Other $877 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,300 5 payments
  2. Food and Beverage $5,249 200 payments
  3. Travel and Lodging $2,142 11 payments
  4. Education $86 2 payments
Products named General payments · program years 2019–2025
  1. Carto 3 System $5,313 14 payments
  2. Carto 3 $2,754 18 payments
  3. MICRA Pacemakers $572 6 payments
  4. ENTRESTO $380 31 payments
  5. ENSITE $311 3 payments
  6. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $281 3 payments
  7. LEQVIO $176 12 payments
  8. Micra Pacemakers $175 3 payments
  9. AVEIR $172 1 payment
  10. Sotalol Hydrochloride $145 1 payment
  11. Other $2,421 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

7,292

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,706,287

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

38.3%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,576 $1,135,615
Multaq Dronedarone Hcl Brand 224 $213,189
Xarelto Rivaroxaban Brand 225 $177,319
Entresto Sacubitril/Valsartan Brand 122 $85,069
Dofetilide Generic 71 $13,271
Metoprolol Succinate Generic 856 $11,935
Propafenone Hcl Er Propafenone Hcl Brand 39 $8,317
Amiodarone Hcl Generic 373 $8,163
Diltiazem 12hr Er Diltiazem Hcl Brand 16 $5,829
Propafenone Hcl Generic 134 $5,229

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$405,243

Medicare's payments for the services billed

Medicare patients

1,834

Average age 78

Services billed

6,583

773 women, 1,061 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 72%
Ischemic heart disease 58%
Heart failure 48%
Arthritis 46%
Diabetes 33%
Chronic kidney disease 30%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $66
$66 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $34
$34 122 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $16
$16 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $15
$15 1,576 —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

218 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record